Clariant to develop chiral APIs with Chiral Quest

Published: 1-Nov-2002


Clariant Pharmaceuticals has signed an agreement with Chiral Quest for the development of manufacturing processes for single enantiomer active pharmaceutical ingredients (APIs).

Under the terms of the agreement, Chiral Quest will work with Clariant Pharmaceutical's r&d group in Sulzbach, Germany, to develop commercially viable processes for a chiral antibiotic API.

The collaboration will pair Chiral Quest's expertise in chiral chemistry and proprietary chiral catalysts with Clariant's strengths in organometallic synthesis and commercial scale cGMP intermediate and API manufacture.

Dr Ralf Pfirmann, Clariant's global business director, said: 'Clariant has undertaken a comprehensive approach to delivering chirality in pharmaceutical synthesis. We are expanding Clariant's capability to support the pharmaceutical industry's quest in exploiting chirality to improve the performance, safety and economics of drugs.'

You may also like